28-01-20, Ypres [les poilus et la foule parmi les ruines lors de la cérémonie de décoration de la Croix de guerre de la ville par M. Poincaré] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57800

15/2/20, M. Poincaré à Thionville [avec à sa droite la grande-duchesse de Luxembourg, cérémonie de remise de la croix d'honneur à la ville] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58019

15/2/20, Thionville, la grande-duchesse Charlotte [de Luxembourg] et M. Poincaré [revue des troupes, le jour de la remise de la croix d'honneur à la ville] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58022

15/2/20, Thionville [M. Poincaré avec à sa droite la grande-duchesse de Luxembourg, cérémonie de remise de la croix d'honneur à la ville] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58024

15/2/20, M. Poincaré à Thionville [avec à sa droite la grande-duchesse de Luxembourg, estrade située place du marché, cérémonie de remise de la croix d'honneur à la ville] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58025

15/2/20, M. Poincaré à Thionville [avec à sa droite la grande-duchesse de Luxembourg, place du marché, défilé de jeunes lorraines en costume, cérémonie de remise de la croix d'honneur à la ville] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58027

16/2/20, M. Poincaré au cimetière de Verdun : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58030

16/2/20, M. Poincaré au cimetière de Verdun : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58031

16/2/20, M. Poincaré à Verdun : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58033

28-12-19, [voyage présidentiel] remise de la Croix de guerre et Légion d'honneur à [la ville d']Arras [vue de la tribune présidentielle] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57362

Testing differentiation in diploid populations.

We examine the power of different exact tests of differentiation for diploid populations. Since there is not necessarily random mating within populations, the appropriate hypothesis to construct exact tests is that of independent sampling of genotypes. There are two categories of tests, FST-estimator tests and goodness of fit tests. In this latter category, we distinguish "allelic statistics", which account for the nature of alleles within genotypes, from "genotypic statistics" that do not. We show that the power of FST-estimator tests and of allelic goodness of fit tests are similar when sampling is balanced, and higher than the power of genotypic goodness of fit tests. When sampling is unbalanced, the most powerful tests are shown to belong to the allelic goodness of fit group.

Prevention of cutaneous melanoma: an epidemiological evaluation of the Swiss campaign.

A national information program, focusing on the main recognized risk factors (primary prevention) and on the potential benefits of early detection (secondary prevention) of cutaneous malignant melanoma, was launched in Switzerland in May 1988. The first campaign, based on a pilot study conducted in 1986 in the canton of Basel, was followed by a recall campaign in July 1989. This report describes the organization of this program and presents an assessment of its initial impact. The number of newly diagnosed cases increased more than twofold (+ 116%) in the two months following the launch of the first campaign (May to June 1988). This trend was accompanied by a statistically significant shift of case distribution towards younger ages (< 60 years; p = 0.003), and a non-significant shift was observed towards less advanced lesions (thickness < or = 1.5 mm). The incidence decreased quickly, though in the twelve month period between the two campaigns it remained 21% higher than before the inception of the program. No appreciable effects were detected from the recall campaign and no difference was seen among regions or between sexes.

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma.

BACKGROUND: Sunitinib (VEGFR/PDGFR inhibitor) and everolimus (mTOR inhibitor) are both approved for advanced renal cell carcinoma (RCC) as first-line and second-line therapy, respectively. In the clinics, sunitinib treatment is limited by the emergence of acquired resistance, leading to a switch to second-line treatment at progression, often based on everolimus. No data have been yet generated on programmed alternating sequential strategies combining alternative use of sunitinib and everolimus before progression. Such strategy is expected to delay the emergence of acquired resistance and improve tumour control. The aim of our study was to assess the changes in tumours induced by three different sequences administration of sunitinib and everolimus. METHODS: In human Caki-1 RCC xenograft model, sunitinib was alternated with everolimus every week, every 2 weeks, or every 3 weeks. Effects on necrosis, hypoxia, angiogenesis, and EMT status were assessed by immunohisochemistry and immunofluorescence. RESULTS: Sunitinib and everolimus programmed sequential regimens before progression yielded longer median time to tumour progression than sunitinib and everolimus monotherapies. In each group of treatment, tumour growth control was associated with inhibition of mTOR pathway and changes from a mesenchymal towards an epithelial phenotype, with a decrease in vimentin and an increase in E-cadherin expression. The sequential combinations of these two agents in a RCC mouse clinical trial induced antiangiogenic effects, leading to tumour necrosis. CONCLUSIONS: In summary, our study showed that alternate sequence of sunitinib and everolimus mitigated the development of mesenchymal phenotype compared with sunitinib as single agent.